Key result
Serum cardiac-specific biomarkers, particularly troponin and B-type natriuretic peptide, are reviewed as potential diagnostic tools for early prediction of chemotherapy-induced cardiotoxicity.
Why the study?
Do serum cardiac biomarkers (troponin, BNP) and emerging imaging techniques improve early prediction of chemotherapy-induced cardiotoxicity in breast cancer patients?
Do serum cardiac biomarkers (troponin, BNP) and emerging imaging techniques improve early prediction of chemotherapy-induced cardiotoxicity in breast cancer patients?
Serum biomarkers like troponin and BNP, along with advanced imaging, may offer earlier detection of chemotherapy-induced cardiotoxicity compared to traditional LVEF monitoring.
Serum biomarkers may enable earlier cardiotoxicity detection than LVEF; leaves open routine adoption pending prospective trials.
Chemotherapy-induced cardiotoxicity, is a well-known and potentially serious complication strongly impacting the quality of life and overall survival of breast cancer patients. The current diagnostic approach to detect cardiac damage is the estimation of left ventricular ejection fraction by echocardiography. However, this approach exhibits less sensitivity toward early prediction of cardiomyopathy, not allowing for preventive strategies. Measurement of serum cardiac-specific biomarkers can be a valid diagnostic tool for identifying patients prone to developing cardiotoxocity and in whom closer cardiac monitoring and preventive strategies are pivotal. In this article, we review work done on biomarkers in recent years, with an emphasis on troponin and B-type natriuretic peptide, which are currently the most studied in this field. We also briefly discuss current and emerging imaging techniques for early detection of cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Chaudry et al. (2016) conducted a review in Chemotherapy-induced cardiotoxicity in breast cancer. Serum cardiac-specific biomarkers (troponin and B-type natriuretic peptide) was evaluated. Serum cardiac-specific biomarkers, particularly troponin and B-type natriuretic peptide, are reviewed as potential diagnostic tools for early prediction of chemotherapy-induced cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: